Anthrax Pathogenesis

Annual Review of Microbiology

Volumn 69, Issue 1, 2015, Pages 185-208

  Moayeri, Mahtab ^a   Leppla, Stephen H ^a   Vrentas, Catherine ^a   Pomerantsev, Andrei P ^a   Liu, Shihui ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax toxins; Edema factor; Lethal factor; Protective antigen

Indexed keywords

AMOXICILLIN; ANTHRAX TOXIN; ANTHRAX VACCINE; CIPROFLOXACIN; INFLAMMASOME; LEVOFLOXACIN; LYMPHOCYTE ANTIGEN RECEPTOR; PENICILLIN DERIVATIVE; RAXIBACUMAB; VIRULENCE FACTOR; BACTERIAL ANTIGEN; BACTERIAL TOXIN;

ANTHRAX; ANTIBODY TITER; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS MYCOIDES; BACILLUS PSEUDOMYCOIDES; BACILLUS THURINGIENSIS; BACILLUS WEIHENSTEPHANENSIS; BACTERIAL VIRULENCE; CONFORMATIONAL TRANSITION; ENDOCYTOSIS; GENE CONTROL; GENETIC VARIABILITY; GENOMICS; HUMAN; INNATE IMMUNITY; MOLECULAR PATHOLOGY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; ANIMAL; BACTERIAL CAPSULE; BACTERIAL SPORE; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; VETERINARY;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL CAPSULES; BACTERIAL TOXINS; HUMANS; SPORES, BACTERIAL;

EID: 84940859321     PISSN: 00664227     EISSN: 15453251     Source Type: Book Series    
DOI: 10.1146/annurev-micro-091014-104523     Document Type: Review

References (279)

1. Abrami L, BischofbergerM, Kunz B, Groux R, van der Goot FG. 2010. Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors. PLOS Pathog. 6: e1000792
2. Abrami L, Brandi L, Moayeri M, Brown MJ, Krantz BA, et al. 2013. Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin. Cell Rep. 5: 986-96
3. Abrami L, Kunz B, van der Goot FG. 2010. Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake. PNAS 107: 1420-24
4. Abrami L, Leppla SH, van der Goot FG. 2006. Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J. Cell Biol. 172: 309-20
5. Abrami L, Lindsay M, Parton RG, Leppla SH, van der Goot FG. 2004. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 166: 645-51
6. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. 2003. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 160: 321-28
7. Agaisse H, Gominet M, Okstad OA, Kolsto AB, Lereclus D. 1999. PlcR is a pleiotropic regulator of extracellular virulence factor gene expression in Bacillus thuringiensis. Mol. Microbiol. 32: 1043-53
8. Agrawal A, Lingappa J, Leppla SH, Agrawal S, Jabbar A, et al. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-34
9. Alileche A, Serfass ER, Muehlbauer SM, Porcelli SA, Brojatsch J. 2005. Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLOS Pathog. 1: e19
10. Arora N, Leppla SH. 1993. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268: 3334-41
11. Aulinger BA, Roehrl MH, Mekalanos JJ, Collier RJ, Wang JY. 2005. Combining anthrax vaccine and therapy: A dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect. Immun. 73: 3408-14
12. Barson HV, Mollenkopf H, Kaufmann SH, Rijpkema S. 2008. Anthrax lethal toxin suppresses chemokine production in human neutrophil NB-4 cells. Biochem. Biophys. Res. Commun. 374: 288-93
13. Bartkus JM, Leppla SH. 1989. Transcriptional regulation of the protective antigen gene of Bacillus anthracis. Infect. Immun. 57: 2295-300
14. Basha S, Rai P, Poon V, Saraph A, Gujraty K, et al. 2006. Polyvalent inhibitors of anthrax toxin that target host receptors. PNAS 103: 13509-13
15. Batty S, Chow EM, Kassam A, Der SD, Mogridge J. 2006. Inhibition of mitogen-activated protein kinase signalling by Bacillus anthracis lethal toxin causes destabilization of interleukin-8 mRNA. Cell. Microbiol. 8: 130-38
16. Beall FA, Dalldorf FG. 1966. The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. 116: 377-89
17. Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, et al. 2011. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis. Clin. Vaccine Immunol. 19: 140-45
18. Bishop BL, Lodolce JP, Kolodziej L, Boone DL, Tang WJ. 2010. The role of anthrolysin O in gut epithelial barrier disruption during Bacillus anthracis infection. Biochem. Biophys. Res. Commun. 394: 254-59
19. Bolcome RE III, Sullivan SE, Zeller R, Barker AP, Collier RJ, Chan J. 2008. Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature. PNAS 105: 2439-44
20. Boyden ED, Dietrich WF. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38: 240-44
21. Boyer AE, Quinn CP, Hoffmaster AR, Kozel TR, Saile E, et al. 2009. Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques. Infect. Immun. 77: 3432-41
22. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414: 225-29
23. Bradley KA, Mogridge J, Rainey GJ, Batty S, Young JA. 2003. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J. Biol. Chem. 278: 49342-47
24. Brittingham KC, Ruthel G, Panchal RG, Fuller CL, Ribot WJ, et al. 2005. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J. Immunol. 174: 5545-52
25. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. 2007. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccin. 3: 205-11
26. Candela T, Dumetz F, Tosi-Couture E, Mock M, Goossens PL, Fouet A. 2012. Cell-wall preparation containing poly-gamma-D-glutamate covalently linked to peptidoglycan, a straightforward extractable molecule, protects mice against experimental anthrax infection. Vaccine 31: 171-75
27. Candela T, Mock M, Fouet A. 2005. CapE, a 47-amino-acid peptide, is necessary for Bacillus anthracis polyglutamate capsule synthesis. J. Bacteriol. 187: 7765-72
28. Cao S, Guo A, Liu Z, Tan Y, Wu G, et al. 2009. Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination. Infect. Immun. 77: 4679-87
29. Cendrowski S, MacArthur W, Hanna P. 2004. Bacillus anthracis requires siderophore biosynthesis for growth in macrophages and mouse virulence. Mol. Microbiol. 51: 407-17
30. Chabot DJ, Joyce J, Caulfield M, Cook J, Hepler R, et al. 2012. Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys. Vaccine 30: 846-52
31. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. 2004. Anthrax capsule vaccine protects against experimental infection. Vaccine 23: 43-47
32. Chang HH, Wang TP, Chen PK, Lin YY, Liao CH, et al. 2013. Erythropoiesis suppression is associated with anthrax lethal toxin-mediated pathogenic progression. PLOS ONE 8: e71718
33. Chateau A, van Schaik W, Six A, AucherW, Fouet A. 2011. CodY regulation is required for full virulence and heme iron acquisition in Bacillus anthracis. FASEB J. 25: 4445-56
34. Chavarria-Smith J, Vance RE. 2013. Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLOS Pathog. 9: e1003452
35. Chen D, Misra M, Sower L, Peterson JW, Kellogg GE, Schein CH. 2008. Novel inhibitors of anthrax edema factor. Bioorg. Med. Chem. 16: 7225-33
36. Chen PK, Chang HH, Lin GL, Wang TP, Lai YL, et al. 2013. Suppressive effects of anthrax lethal toxin on megakaryopoiesis. PLOS ONE 8: e59512
37. Chen Z, Moayeri M, Purcell R. 2011. Monoclonal antibody therapies against anthrax. Toxins 3: 1004-19
38. Chen Z, Schneerson R, Lovchik J, Lyons CR, Zhao H, et al. 2010. Pre-and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. PNAS 108: 739-44
39. Chiang C, Bongiorni C, Perego M. 2011. Glucose-dependent activation of Bacillus anthracis toxin gene expression and virulence requires the carbon catabolite protein CcpA. J. Bacteriol. 193: 52-62
40. Chitlaru T, Altboum Z, Reuveny S, Shafferman A. 2011. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol. Rev. 239: 221-36
41. Chitlaru T, Shafferman A. 2009. Proteomic studies of Bacillus anthracis. Future Microbiol. 4: 983-98
42. Chitlaru T, Zaide G, Ehrlich S, Inbar I, Cohen O, Shafferman A. 2011. HtrA is a major virulence determinant of Bacillus anthracis. Mol. Microbiol. 81: 1542-59
43. Chung MC, Popova TG, Jorgensen SC, Dong L, Chandhoke V, et al. 2008. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J. Biol. Chem. 283: 9531-42
44. Cleret A, Quesnel-Hellmann A, Mathieu J, Vidal D, Tournier JN. 2006. Resident CD11c+ lung cells are impaired by anthrax toxins after spore infection. J. Infect. Dis. 194: 86-94
45. Cleret-Buhot A, Mathieu J, Tournier JN, Quesnel-Hellmann A. 2012. Both lethal and edema toxins of Bacillus anthracis disrupt the human dendritic cell chemokine network. PLOS ONE 7: e43266
46. Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, et al. 2013. The sepsis model: An emerging hypothesis for the lethality of inhalation anthrax. J. Cell Mol. Med. 17: 914-20
47. Collier RJ. 2009. Membrane translocation by anthrax toxin. Mol. Aspects Med. 30: 413-22
48. Corre JP, Piris-Gimenez A, Moya-Nilges M, Jouvion G, Glomski IJ, et al. 2012. In vivo germination of Bacillus anthracis spores during murine cutaneous infection. J. Infect. Dis. 207: 450-57
49. Crawford MA, Aylott CV, Bourdeau RW, Bokoch GM. 2006. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. 176: 7557-65
50. Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, et al. 2013. Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. J. Biomol. Screen. 18: 714-25
51. Cui X, Li Y, Li X, Haley M, Moayeri M, et al. 2006. Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis. 193: 829-40
52. Cui X, Moayeri M, Li Y, Li X, Haley M, et al. 2004. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286: R699-709
53. Cunningham K, Lacy DB, Mogridge J, Collier RJ. 2002. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. PNAS 99: 7049-53
54. D'Agnillo F, WilliamsMC, MoayeriM, Warfel JM. 2013. Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLOS ONE 8: e62576
55. Dai Z, Sirard JC, Mock M, Koehler TM. 1995. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. Mol. Microbiol. 16: 1171-81
56. Dal Molin F, Fasanella A, Simonato M, Garofolo G, Montecucco C, Tonello F. 2008. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 52: 824-28
57. Dalldorf FG, Beall FA. 1967. Capillary thrombosis as a cause of death in experimental anthrax. Arch. Pathol. 83: 154-61
58. Drobniewski FA. 1993. Bacillus cereus and related species. Clin. Microbiol. Rev. 6: 324-38
59. Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, et al. 2002. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415: 396-402
60. Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TM. 2004. AtxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J. Bacteriol. 186: 307-15
61. Drysdale M, Bourgogne A, Koehler TM. 2005. Transcriptional analysis of the Bacillus anthracis capsule regulators. J. Bacteriol. 187: 5108-14
62. Drysdale M, Heninger S, Hutt J, Chen Y, Lyons CR, Koehler TM. 2005. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24: 221-27
63. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-37
64. During RL, Gibson BG, Li W, Bishai EA, Sidhu GS, et al. 2007. Anthrax lethal toxin paralyzes actinbased motility by blocking Hsp27 phosphorylation. EMBO J. 26: 2240-50
65. During RL, LiW, Hao B, Koenig JM, StephensDS, et al. 2005. Anthrax lethal toxin paralyzes neutrophil actin-based motility. J. Infect. Dis. 192: 837-45
66. Ebrahimi CM, Sheen TR, Renken CW, Gottlieb RA, Doran KS. 2011. Contribution of lethal toxin and edema toxin to the pathogenesis of anthrax meningitis. Infect. Immun. 79: 2510-18
67. Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM, Chanh TC. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. 69: 1175-77
68. Feinen B, Petrovsky N, Verma A, Merkel TJ. 2014. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin. Vaccine Immunol. 21: 580-86
69. Feld GK, Brown MJ, Krantz BA. 2012. Ratcheting up protein translocation with anthrax toxin. Protein Sci. 21: 606-24
70. Firoved AM, Miller GF, MoayeriM, Kakkar R, Shen Y, et al. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167: 1309-20
71. Fish DC, Klein F, Lincoln RE, Walker JS, Dobbs JP. 1968. Pathophysiological changes in the rat associated with anthrax toxin. J. Infect. Dis. 118: 114-24
72. Fish DC, Lincoln RE. 1967. Biochemical and biophysical characterization of anthrax toxin. Fed. Proc. 26: 1534-38
73. Fish DC, Lincoln RE. 1968. In vivo-produced anthrax toxin. J. Bacteriol. 95: 919-24
74. Fouet A. 2010. AtxA, a Bacillus anthracis global virulence regulator. Res. Microbiol. 161: 735-42
75. Friedlander AM. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261: 7123-26
76. Friedlander AM, Little SF. 2009. Advances in the development of next-generation anthrax vaccines. Vaccine 27(Suppl. 4): D28-32
77. Froude JW, Thullier P, Pelat T. 2011. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins 3: 1433-52
78. Garcia AA, Fels RJ, Mosher LJ, Kenney MJ. 2012. Bacillus anthracis lethal toxin alters regulation of visceral sympathetic nerve discharge. J. Appl. Physiol. 112: 1033-40
79. Garufi G, Wang YT, Oh SY, Maier H, Missiakas DM, Schneewind O. 2012. Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis. Vaccine 30: 3435-44
80. Gat O, Grosfeld H, Ariel N, Inbar I, Zaide G, et al. 2006. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect. Immun. 74: 3987-4001
81. Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, et al. 2005. The solute-binding component of a putativeMn(II)ABCtransporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol. Microbiol. 58: 533-51
82. Gat O, Zaide G, Inbar I, Grosfeld H, Chitlaru T, et al. 2008. Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains. Mol. Microbiol. 70: 983-99
83. Gleiser CA. 1967. Pathology of anthrax infection in animal hosts. Fed. Proc. 26: 1518-21
84. Gleiser CA, Berdjis CC, Hartman HA, Gochenour WS. 1963. Pathology of experimental respiratory anthrax in Macaca mulatta. Br. J. Exp. Pathol. 44: 416-26
85. GoharM, Faegri K, Perchat S, Ravnum S, Okstad OA, et al. 2008. The PlcR virulence regulon of Bacillus cereus. PLOS ONE 3: e2793
86. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, et al. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, doubleblinded, controlled, multicenter trial. Vaccine 24: 5950-59
87. Guichard A, McGillivray SM, Cruz-Moreno B, van Sorge NM, Nizet V, Bier E. 2010. Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature 467: 854-58
88. Guichard A, Nizet V, Bier E. 2011. New insights into the biological effects of anthrax toxins: linking cellular to organismal responses. Microbes Infect. 14: 97-118
89. Guichard A, Park JM, Cruz-Moreno B, Karin M, Bier E. 2006. Anthrax lethal factor and edema factor act on conserved targets in Drosophila. PNAS 103: 3244-49
90. Guignot J, Mock M, Fouet A. 1997. AtxA activates the transcription of genes harbored by both Bacillus anthracis virulence plasmids. FEMS Microbiol. Lett. 147: 203-7
91. Guo Q, Shen Y, Zhukovskaya NL, Florian J, Tang WJ. 2004. Structural and kinetic analyses of the interaction of anthrax adenylyl cyclase toxin with reaction products cAMP and pyrophosphate. J. Biol. Chem. 279: 29427-35
92. Hammerstrom TG, Roh J, Nikonowicz EP, Koehler TM. 2011. Bacillus anthracis virulence regulator AtxA: oligomeric state, function, and CO2-signalling. Mol. Microbiol. 82: 634-47
93. Harrell LJ, Andersen GL, Wilson KH. 1995. Genetic variability of Bacillus anthracis and related species. J. Clin. Microbiol. 33: 1847-50
94. Heffernan BJ, Thomason B, Herring-Palmer A, Hanna P. 2007. Bacillus anthracis anthrolysinOand three phospholipases C are functionally redundant in a murine model of inhalation anthrax. FEMS Microbiol. Lett. 271: 98-105
95. Helgason E, Okstad OA, Caugant DA, Johansen HA, Fouet A, et al. 2000. Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis-one species on the basis of genetic evidence. Appl. Environ. Microbiol. 66: 2627-30
96. Hellmich KA, Levinsohn JL, Fattah R, Newman ZL, Maier N, et al. 2012. Anthrax lethal factor cleaves mouse Nlrp1b in both toxin-sensitive and toxin-resistant macrophages. PLOS ONE 7: e49741
97. Hicks CW, Li Y, Okugawa S, Solomon SB, Moayeri M, et al. 2011. Anthrax edema toxin has cAMPmediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. Am. J. Physiol. Heart Circ. Physiol. 300: H1108-18
98. Hoffmaster AR, Hill KK, Gee JE, Marston CK, De BK, et al. 2006. Characterization of Bacillus cereus isolates associated with fatal pneumonias: Strains are closely related to Bacillus anthracis and harbor B. Anthracis virulence genes. J. Clin. Microbiol. 44: 3352-60
99. Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, ChuteMD, et al. 2004. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. PNAS 101: 8449-54
100. Hopkins RJ, Howard C, Hunter-Stitt E, Kaptur PE, Pleune B, et al. 2014. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax R regimen for post-exposure prophylaxis in healthy adults. Vaccine 32: 2217-24
101. Hu H, Sa Q, Koehler TM, Aronson AI, Zhou D. 2006. Inactivation of Bacillus anthracis spores in murine primary macrophages. Cell. Microbiol. 8: 1634-42
102. Hu X, Van der Auwera G, Timmery S, Zhu L, Mahillon J. 2009. Distribution, diversity and potential mobility of extra-chromosomal elements related to the Bacillus anthracis pXO1 and pXO2 virulence plasmids. Appl. Environ. Microbiol. 75: 3016-28
103. Hutt JA, Lovchik JA, Drysdale M, Sherwood RL, Brasel T, et al. 2014. Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge. Am. J. Pathol. 184: 3205-16
104. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, et al. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-48
105. Jelacic TM, Chabot DJ, Bozue JA, Tobery SA, West MW, et al. 2014. Exposure to Bacillus anthracis capsule results in suppression of human monocyte-derived dendritic cells. Infect. Immun. 82: 3405-16
106. Jenkins A, Cote C, Twenhafel N, Merkel T, Bozue J, Welkos S. 2010. Role of purine biosynthesis in Bacillus anthracis pathogenesis and virulence. Infect. Immun. 79: 153-66
107. Jenkins SA, Xu Y. 2013. Characterization of Bacillus anthracis persistence in vivo. PLOS ONE 8: e66177
108. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, et al. 2001. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 7: 933-44
109. Jiao GS, Kim S, MoayeriM, Cregar-Hernandez L, McKasson L, et al. 2010. Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy. Bioorg. Med. Chem. Lett. 20: 6850-53
110. Jiao GS, Kim S, MoayeriM, Crown D, Thai A, et al. 2012. Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg. Med. Chem. Lett. 22: 2242-46
111. Jones WI Jr, Klein F, Walker JS, Mahlandt BG, Dobbs JP, Lincoln RE. 1967. In vivo growth and distribution of anthrax bacilli in resistant, susceptible, and immunized hosts. J. Bacteriol. 94: 600-8
112. Joyce JG, Cook J, Chabot D, Hepler R, Shoop W, et al. 2006. Immunogenicity and protective efficacy of Bacillus anthracis poly-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 281: 4831-43
113. KandadiMR, Hua Y, MaH, LiQ, Kuo SR, et al. 2010. Anthrax lethal toxin suppressesmurine cardiomyocyte contractile function and intracellular Ca2+ handling via aNADPH oxidase-dependentmechanism. PLOS ONE 5: e13335
114. Karginov VA, Nestorovich EM, Moayeri M, Leppla SH, Bezrukov SM. 2005. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. PNAS 102: 15075-80
115. Kau JH, Sun DS, Huang HS, Lien TS, Huang HH, et al. 2010. Sublethal doses of anthrax lethal toxin on the suppression of macrophage phagocytosis. PLOS ONE 5: e14289
116. Kaur M, Singh S, Bhatnagar R. 2013. Anthrax vaccines: Present status and future prospects. Expert. Rev. Vaccines 12: 955-70
117. Keim P, Price LB, Klevytska AM, Smith KL, Schupp JM, et al. 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J. Bacteriol. 182: 2928-36
118. Keitel WA. 2006. Recombinant protective antigen 102 (rPA102): Profile of a second-generation anthrax vaccine. Expert Rev. Vaccines 5: 417-30
119. Kern J, Schneewind O. 2010. BslA, the S-layer adhesin of B. Anthracis, is a virulence factor for anthrax pathogenesis. Mol. Microbiol. 75: 324-32
120. Kim C, Wilcox-Adelman S, Sano Y, Tang WJ, Collier RJ, Park JM. 2008. Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus. PNAS 105: 6150-55
121. Kim S, Jiao GS, Moayeri M, Crown D, Cregar-Hernandez L, et al. 2011. Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy. Bioorg. Med. Chem. Lett. 21: 2030-33
122. Kintzer AF, Thoren KL, SterlingHJ, Dong KC, Feld GK, et al. 2009. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 392: 614-29
123. Klee SR, OzelM, Appel B, Boesch C, Ellerbrok H, et al. 2006. Characterization of Bacillus anthracis-like bacteria isolated from wild great apes from Côte d'Ivoire and Cameroon. J. Bacteriol. 188: 5333-44
124. Klein F, Hodges DR, Mahlandt BG, Jones WI, Haines BW, Lincoln RE. 1962. Anthrax toxin: causative agent in the death of rhesus monkeys. Science 138: 1331-33
125. Klein F, Walker JS, Fitzpatrick DF, Lincoln RE, Mahlandt BG, et al. 1966. Pathophysiology of anthrax. J. Infect. Dis. 116: 123-38
126. Klimpel KR, Arora N, Leppla SH. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13: 1093-100
127. Klimpel KR, Leppla SH, Singh Y, Quinn CP. 1992. Fine structure analysis of the amino acid sequence recognized by the eukaryotic cell protease that activates anthrax toxin. In Bacterial Protein Toxins, ed. BWitholt, JE Alouf, GJ Boulnois, P Cossart, BWDijkstra, et al. , pp. 490-91. Stuttgart, Germ.: Gustav Fischer
128. Koehler TM, Dai Z, Kaufman-Yarbray M. 1994. Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters. J. Bacteriol. 176: 586-95
129. Koppisch AT, Browder CC, Moe AL, Shelley JT, Kinkel BA, et al. 2005. Petrobactin is the primary siderophore synthesized by Bacillus anthracis str. Sterne under conditions of iron starvation. Biometals 18: 577-85
130. Kozel TR, Thorkildson P, Brandt S, Welch WH, Lovchik JA, et al. 2007. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun. 75: 152-63
131. Krantz BA, Finkelstein A, Collier RJ. 2005. Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient. J. Mol. Biol. 355: 968-79
132. Krantz BA, Melnyk RA, Zhang S, Juris SJ, Lacy DB, et al. 2005. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309: 777-81
133. Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, et al. 2008. Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb. Pathog. 44: 467-72
134. Lacy DB, Mourez M, Fouassier A, Collier RJ. 2002. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. 277: 3006-10
135. Langer M, Duggan ES, Booth JL, Patel VI, Zander RA, et al. 2012. Bacillus anthracis lethal toxin reduces human alveolar epithelial barrier function. Infect. Immun. 80: 4374-87
136. Leffel EK, Bourdage JS, Williamson ED, DucharsM, Fuerst TR, Fusco PC. 2012. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Clin. Vaccine Immunol. 19: 1158-64
137. Lehmann M, Noack D, Wood M, Perego M, Knaus UG. 2009. Lung epithelial injury by B. Anthracis lethal toxin is caused by MKK-dependent loss of cytoskeletal integrity. PLOS ONE 4: e4755
138. Leppla SH. 1982. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. PNAS 79: 3162-66
139. Leppla SH. 1984. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv. Cycl. Nucleotide Protein Phosphorylation Res. 17: 189-98
140. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, GetzMA, et al. 2012. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLOS Pathog. 8: e1002638
141. Levy H, Glinert I, Weiss S, Sittner A, Schlomovitz J, et al. 2014. Toxin-independent virulence of Bacillus anthracis in rabbits. PLOS ONE 9: e84947
142. Levy H, Weiss S, Altboum Z, Schlomovitz J, Glinert I, et al. 2012. Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models. Infect. Immun. 80: 2623-31
143. Levy H, Weiss S, Altboum Z, Schlomovitz J, Rothschild N, et al. 2011. Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits. Microb. Pathog. 51: 345-51
144. Levy H, Weiss S, Altboum Z, Schlomovitz J, Rothschild N, et al. 2011. The effect of deletion of the edema factor on Bacillus anthracis pathogenicity in guinea pigs and rabbits. Microb. Pathog. 52: 55-60
145. Li Y, Cui X, Su J, Haley M, Macarthur H, et al. 2009. Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit. Care Med. 37: 1348-54
146. Lincoln RE, Hodges DR, Klein F, Mahlandt BG, Jones WI Jr, et al. 1965. Role of the lymphatics in the pathogenesis of anthrax. J. Infect. Dis. 115: 481-94
147. Lincoln RE, Walker JS, Klein F, Rosenwald AJ, JonesWI Jr. 1967. Value of field data for extrapolation in anthrax. Fed. Proc. 26: 1558-62
148. Little SF, Ivins BE, Fellows PF, PittML, Norris SL, AndrewsGP. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-30
149. Liu S, Crown D, Miller-Randolph S, MoayeriM, WangH, et al. 2009. Capillarymorphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. PNAS 106: 12424-29
150. Liu S, Leppla SH. 2003. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 278: 5227-34
151. Liu S, Leung HJ, Leppla SH. 2007. Characterization of the interaction between anthrax toxin and its cellular receptors. Cell. Microbiol. 9: 977-87
152. Liu S, Miller-Randolph S, Crown D, Moayeri M, Sastalla I, et al. 2010. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 8: 455-62
153. Liu S, Zhang Y, Moayeri M, Liu J, Crown D, et al. 2013. Key tissue targets responsible for anthraxtoxin-induced lethality. Nature 501: 63-68
154. Lovchik JA, Drysdale M, Koehler TM, Hutt JA, Lyons CR. 2012. Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbitmodel of inhalational anthrax. Infect. Immun. 80: 2414-25
155. Lowe DE, Glomski IJ. 2012. Cellular and physiological effects of anthrax exotoxin and its relevance to disease. Front. Cell Infect. Microbiol. 2: 76
156. Mabry R, Brasky K, Geiger R, Carrion R Jr, Hubbard GB, et al. 2006. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin. Vaccine Immunol. 13: 671-77
157. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. 1989. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 171: 722-30
158. Makino S, Watarai M, Cheun HI, Shirahata T, Uchida I. 2002. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J. Infect. Dis. 186: 227-33
159. Maresso AW, Garufi G, Schneewind O. 2008. Bacillus anthracis secretes proteins that mediate heme acquisition from hemoglobin. PLOS Pathog. 4: e1000132
160. McGillivray SM, Ebrahimi CM, Fisher N, Sabet M, Zhang DX, et al. 2009. ClpX contributes to innate defense peptide resistance and virulence phenotypes of Bacillus anthracis. J. Innate Immun. 1: 494-506
161. McKenzie AT, Pomerantsev AP, Sastalla I, Martens C, Ricklefs SM, et al. 2014. Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism. BMC Genomics 15: 229
162. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, et al. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266: 1202-8
163. MigoneTS, SubramanianGM, Zhong J, HealeyLM, CoreyA, et al. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361: 135-44
164. Miller CJ, Elliott JL, Collier RJ. 1999. Anthrax protective antigen: Prepore-to-pore conversion. Biochemistry 38: 10432-41
165. Milne JC, Collier RJ. 1993. PH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10: 647-53
166. Milne JC, FurlongD, Hanna PC, Wall JS, Collier RJ. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269: 20607-12
167. Moayeri M, Crown D, Dorward DW, Gardner D, Ward JM, et al. 2009. The heart is an early target of anthrax lethal toxin in mice: A protective role for neuronal nitric oxide synthase (nNOS). PLOS Pathog. 4: e1000456
168. MoayeriM, Crown D, Jiao GS, Kim S, Johnson A, et al. 2013. Small molecule inhibitors of lethal factor protease activity protect against anthrax infection. Antimicrob. Agents Chemother. 57: 4139-45
169. MoayeriM, Crown D, Newman ZL, Okugawa S, EckhausM, et al. 2010. Inflammasome sensor Nlrp1bdependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLOS Pathog. 6: e1001222
170. Moayeri M, Haines D, Young HA, Leppla SH. 2003. Bacillus anthracis lethal toxin induces TNF-independent hypoxia-mediated toxicity in mice. J. Clin. Investig. 112: 670-82
171. MoayeriM, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30: 439-55
172. Moayeri M, Martinez NW, Wiggins J, Young HA, Leppla SH. 2004. Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controllingmacrophage sensitivity. Infect. Immun. 72: 4439-47
173. Moayeri M, Sastalla I, Leppla SH. 2011. Anthrax and the inflammasome. Microbes Infect. 14: 392-400
174. MoayeriM, Webster JI, Wiggins JF, Leppla SH, Sternberg EM. 2005. Endocrine perturbation increases susceptibility of mice to anthrax lethal toxin. Infect. Immun. 73: 4238-44
175. Mogridge J, Cunningham K, Collier RJ. 2002. Stoichiometry of anthrax toxin complexes. Biochemistry 41: 1079-82
176. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. 2002. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. PNAS 99: 7045-48
177. Mogridge J, Mourez M, Collier RJ. 2001. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J. Bacteriol. 183: 2111-16
178. Mourez M, Kane RS, Mogridge J, Metallo S, Deschatelets P, et al. 2001. Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. 19: 958-61
179. Muehlbauer SM, Evering TH, Bonuccelli G, Squires RC, Ashton AW, et al. 2007. Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle 6: 758-66
180. Nestorovich EM, Bezrukov SM. 2012. Obstructing toxin pathways by targeted pore blockage. Chem. Rev. 112: 6388-6430
181. Nestorovich EM, Bezrukov SM. 2014. Designing inhibitors of anthrax toxin. Expert. Opin. Drug Discov. 9: 299-318
182. Newman ZL, Printz MP, Liu S, Crown D, Breen L, et al. 2010. Susceptibility to anthrax lethal toxininduced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLOS Pathog. 6: e1000906
183. Nordberg BK, Schmiterlow CG, Hansen HJ. 1961. Pathophysiological investigations into the terminal course of experimental anthrax in the rabbit. Acta Pathol. Microbiol. Scand. 53: 295-318
184. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla SH. 1985. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47: 306-10
185. Okinaka RT, Cloud K, Hampton O, Hoffmaster AR, Hill KK, et al. 1999. Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J. Bacteriol. 181: 6509-15
186. Okugawa S, Moayeri M, Eckhaus MA, Crown D, Miller-Randolph S, et al. 2011. MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function. Infect. Immun. 79: 118-24
187. Opal SM, Artenstein AW, Cristofaro PA, Jhung JW, Palardy JE, et al. 2005. Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Infect. Immun. 73: 5101-5
188. Oscherwitz J, Yu F, Cease KB. 2010. A synthetic peptide vaccine directed against the 22-23 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J. Immunol. 185: 3661-68
189. Oscherwitz J, Yu F, Jacobs JL, Cease KB. 2013. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax. Clin. Vaccine Immunol. 20: 341-49
190. Paccani SR, Tonello F, Patrussi L, Capitani N, Simonato M, et al. 2007. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microb. 9: 924-29
191. Pannifer AD, Wong TY, Schwarzenbacher R, RenatusM, Petosa C, et al. 2001. Crystal structure of the anthrax lethal factor. Nature 414: 229-33
192. Pannucci J, Okinaka RT, Sabin R, Kuske CR. 2002. Bacillus anthracis pXO1 plasmid sequence conservation among closely related bacterial species. J. Bacteriol. 184: 134-41
193. Park JM, Greten FR, Li ZW, Karin M. 2002. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297: 2048-51
194. Pellizzari R, Guidi-RontaniC, Vitale G, Mock M, Montecucco C. 2000. Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: Analysis of the intracellular consequences in macrophages. Int. J. Med. Microbiol. 290: 421-27
195. Perez CR, Lopez-Perez D, Chmielewski J, Lipton M. 2012. Small molecule inhibitors of anthrax toxininduced cytotoxicity targeted against protective antigen. Chem. Biol. Drug Des. 79: 260-69
196. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385: 833-38
197. Pezard C, Berche P, MockM. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59: 3472-77
198. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, et al. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19: 4768-73
199. Pomerantsev AP, Camp A, Leppla SH. 2009. A new minimal replicon of Bacillus anthracis plasmid pXO1. J. Bacteriol. 191: 5134-46
200. Pomerantsev AP, Chang Z, Rappole C, Leppla SH. 2014. Identification of three noncontiguous regions on Bacillus anthracis plasmid pXO1 that are important for its maintenance. J. Bacteriol. 196: 2921-33
201. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, et al. 2012. A three dose intramuscular schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol. 19: 1730-45
202. Rainey GJ, Wigelsworth DJ, Ryan PL, Scobie HM, Collier RJ, Young JA. 2005. Receptor-specific requirements for anthrax toxin delivery into cells. PNAS 102: 13278-83
203. Ramsay CN, Stirling A, Smith J, HawkinsG, Brooks T, et al. 2010. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro. Surveill. 15: 19465
204. Rasko DA, Altherr MR, Han CS, Ravel J. 2005. Genomics of the Bacillus cereus group of organisms. FEMS Microbiol. Rev. 29: 303-29
205. Rasko DA, Ravel J, Okstad OA, Helgason E, Cer RZ, et al. 2004. The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic adaptations and a large plasmid related to Bacillus anthracis pXO1. Nucleic Acids Res. 32: 977-88
206. Ravel J, Jiang L, Stanley ST, Wilson MR, Decker RS, et al. 2009. The complete genome sequence of Bacillus anthracis Ames "Ancestor". J. Bacteriol. 191: 445-46
207. Raymond B, Batsche E, Boutillon F, Wu YZ, Leduc D, et al. 2009. Anthrax lethal toxin impairs IL-8 expression in epithelial cells through inhibition of histone H3 modification. PLOS Pathog. 5: e1000359
208. Read TD, Salzberg SL, PopM, Shumway M, Umayam L, et al. 2002. Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis. Science 296: 2028-33
209. Reig N, Jiang A, Couture R, Sutterwala FS, Ogura Y, et al. 2008. Maturation modulates caspase-1-independent responses of dendritic cells to anthrax lethal toxin. Cell. Microbiol. 10: 1190-207
210. Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, et al. 2010. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int. J. Biochem. Cell Biol. 42: 987-
211. Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. PNAS 100: 10925-30
212. Ribot WJ, Panchal RG, Brittingham KC, Ruthel G, Kenny TA, et al. 2006. Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun. 74: 5029-34
213. Richter S, Anderson VJ, Garufi G, Lu L, Budzik JM, et al. 2009. Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin. Mol. Microbiol. 71: 404-20
214. Riddle V, Leese P, Blanset D, Adamcio M, Meldorf M, Lowy I. 2011. Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Vaccine Immunol. 18: 2136-42
215. Rolando M, Stefani C, Flatau G, Auberger P, Mettouchi A, et al. 2010. Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity. Cell. Microbiol. 12: 891-905
216. Rosovitz MJ, Schuck P, Varughese M, Chopra AP, Mehra V, et al. 2003. Alanine scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278: 30936-44
217. Ross JM. 1955. On the histopathology of experimental anthrax in the guinea-pig. Br. J. Exp. Pathol. 36: 336-39
218. Ross JM. 1957. The pathogenesis of anthrax following administration of spores by the respiratory route. J. Pathol. Bacteriol. 73: 485-94
219. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, et al. 2011. Marked enhancement of the immune response to BioThrax R (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29: 6313-20
220. Sastalla I, Maltese L, Pomerantseva OM, Pomerantsev AP, Keane-Myers A, Leppla SH. 2010. Activation of the latent PlcR regulon in Bacillus anthracis. Microbiology 156: 2982-93
221. Sastalla I, Tang S, Crown D, Liu S, Eckhaus MA, et al. 2011. Anthrax edema toxin impairs protein clearance in mice. Infect. Immun. 80: 529-38
222. Schein CH, Chen D, Ma L, Kanalas JJ, Gao J, et al. 2012. Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor. Toxins 4: 1288-300
223. Schneerson R, Kubler-Kielb J, Liu TY, Dai ZD, Leppla SH, et al. 2003. Poly(-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: A potential addition to the anthrax vaccine. PNAS 100: 8945-50
224. Scobie HM, Rainey GJ, Bradley KA, Young JA. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. PNAS 100: 5170-74
225. Scobie HM, Thomas D, Marlett JM, Destito G, Wigelsworth DJ, et al. 2005. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 192: 1047-51
226. Scorpio A, Chabot DJ, Day WA, Hoover TA, Friedlander AM. 2010. Capsule depolymerase overexpression reduces Bacillus anthracis virulence. Microbiology 156: 1459-67
227. Scorpio A, Tobery SA, Ribot WJ, Friedlander AM. 2008. Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob. Agents Chemother. 52: 1014-20
228. Seifert R, Dove S. 2013. Inhibitors of Bacillus anthracis edema factor. Pharmacol. Ther. 140: 200-12
229. Sellman BR, Mourez M, Collier RJ. 2001. Dominant-negative mutants of a toxin subunit: An approach to therapy of anthrax. Science 292: 695-97
230. Shannon JG, Ross CL, Koehler TM, Rest RF. 2003. Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin. Infect. Immun. 71: 3183-89
231. Sharma S, Thomas D, Marlett J, Manchester M, Young JA. 2009. Efficient neutralization of antibodyresistant forms of anthrax toxin by a soluble receptor decoy inhibitor. Antimicrob. Agents Chemother. 53: 1210-12
232. Shatalin K, Gusarov I, Avetissova E, Shatalina Y, McQuade LE, et al. 2008. Bacillus anthracis-derived nitric oxide is essential for pathogen virulence and survival in macrophages. PNAS 105: 1009-13
233. Shen Y, Guo Q, Zhukovskaya NL, Drum CL, Bohm A, Tang WJ. 2004. Structure of anthrax edema factor-calmodulin-adenosine 5-(methylene)-triphosphate complex reveals an alternative mode of ATP binding to the catalytic site. Biochem. Biophys. Res. Commun. 317: 309-14
234. Shen Y, Lee YS, Soelaiman S, Bergson P, LuD, et al. 2002. Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J. 21: 6721-32
235. Shen Y, Zhukovskaya NL, Zimmer MI, Soelaiman S, Bergson P, et al. 2004. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. PNAS 101: 3242-47
236. Sherer K, Li Y, Cui X, Li X, Subramanian M, et al. 2007. Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit. Care Med. 35: 1560-67
237. Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, et al. 2005. Anthrax lethal factor inhibition. PNAS 102: 7958-63
238. Singh Y, Klimpel KR, AroraN, SharmaM, Leppla SH. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269: 29039-46
239. Sirard JC, Mock M, Fouet A. 1994. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J. Bacteriol. 176: 5188-92
240. Smith H. 2000. Discovery of the anthrax toxin: The beginning of in vivo studies on pathogenic bacteria. Trends Microbiol. 8: 199-200
241. Smith H, Keppie J. 1962. The terminal phase of anthrax. Br. J. Exp. Pathol. 43: 684-86
242. Smith H, Keppie J, Ross JM, Stanley JL. 1954. Observations on the cause of death in experimental anthrax. Lancet 267: 474-76
243. Solano-Collado V, Lurz R, Espinosa M, Bravo A. 2013. The pneumococcal MgaSpn virulence transcriptional regulator generates multimeric complexes on linear double-stranded DNA. Nucleic Acids Res. 41: 6975-91
244. Sun C, Fang H, Xie T, Auth RD, Patel N, et al. 2012. Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria. PLOS ONE 7: e33583
245. Szarowicz SE, During RL, Li W, Quinn CP, Tang WJ, Southwick FS. 2009. Bacillus anthracis edema toxin impairs neutrophil actin-based motility. Infect. Immun. 77: 2455-64
246. Terra JK, Cote CK, France B, Jenkins AL, Bozue JA, et al. 2010. Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J. Immunol. 184: 17-20
247. Thomas D, Naughton J, Cote C, Welkos S, ManchesterM, Young JA. 2012. Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment. PLOS ONE 7: e34611
248. Tinsley E, Naqvi A, Bourgogne A, Koehler TM, Khan SA. 2004. Isolation of a minireplicon of the virulence plasmid pXO2 of Bacillus anthracis and characterization of the plasmid-encoded RepS replication protein. J. Bacteriol. 186: 2717-23
249. Tournier JN, Quesnel-Hellmann A, Mathieu J, Montecucco C, Tang WJ, et al. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174: 4934-41
250. Tournier JN, Rossi PS, Quesnel-Hellmann A, Baldari CT. 2009. Anthrax toxins: A weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 30: 456-66
251. Tsvetanova B, Wilson AC, Bongiorni C, Chiang C, Hoch JA, Perego M. 2007. Opposing effects of histidine phosphorylation regulate the AtxA virulence transcription factor in Bacillus anthracis. Mol. Microbiol. 63: 644-55
252. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52: 356-63
253. Uchida I, Hornung JM, Thorne CB, Klimpel KR, Leppla SH. 1993. Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. J. Bacteriol. 175: 5329-38
254. Uchida I, Makino S, Sekizaki T, Terakado N. 1997. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. Mol. Microbiol. 23: 1229-40
255. Uchida M, Harada T, Enkhtuya J, Kusumoto A, Kobayashi Y, et al. 2012. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice. Biochem. Biophys. Res. Commun. 421: 323-28
256. Ulmer TS, Soelaiman S, Li S, Klee CB, TangWJ, Bax A. 2003. Calcium dependence of the interaction between calmodulin and anthrax edema factor. J. Biol. Chem. 278: 29261-66
257. Van Ert MN, Easterday WR, Huynh LY, Okinaka RT, Hugh-Jones ME, et al. 2007. Global genetic population structure of Bacillus anthracis. PLOS ONE 2: e461
258. van Sorge NM, Ebrahimi CM, McGillivray SM, Quach D, Sabet M, et al. 2008. Anthrax toxins inhibit neutrophil signaling pathways in brain endothelium and contribute to the pathogenesis of meningitis. PLOS ONE 3: e 2964
259. Vitale G, Bernardi L, Napolitani G, MockM, Montecucco C. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352(Pt 3): 739-45
260. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248: 706-11
261. von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, et al. 2012. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490: 107-11
262. Walker JS, Lincoln RE, Klein F. 1967. Pathophysiological and biochemical changes in anthrax. Fed. Proc. 26: 1539-44
263. Warfel JM, D'Agnillo F. 2011. Anthrax lethal toxin-mediated disruption of endothelial VE-cadherin is attenuated by inhibition of the Rho-associated kinase pathway. Toxins 3: 1278-93
264. Warfel JM, Steele AD, D'Agnillo F. 2005. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 166: 1871-81
265. Watson LE, Kuo SR, Katki K, Dang T, Park SK, et al. 2007. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLOS ONE 2: e466
266. Webster JI, Sternberg EM. 2005. Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo. Mol. Cell Endocrinol. 241: 21-31
267. Webster JI, Tonelli LH, Moayeri M, Simons SS Jr, Leppla SH, Sternberg EM. 2003. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. PNAS 100: 5706-11
268. Wein AN, Williams B, Liu S, Ermolinsky B, Provenzano D, et al. 2012. Small molecule inhibitors of Bacillus anthracis protective antigen proteolytic activation and oligomerization. J. Med. Chem. 55: 7998-8006
269. Weiner ZP, Ernst SM, Boyer AE, Gallegos-Candela M, Barr JR, Glomski IJ. 2013. Circulating lethal toxin decreases the ability of neutrophils to respond to Bacillus anthracis. Cell. Microbiol. 16: 504-18
270. Weiss S, Kobiler D, Levy H, Marcus H, Pass A, et al. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74: 394-98
271. Welkos S, Friedlander A, Weeks S, Little S, Mendelson I. 2002. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 51: 821-31
272. Wickliffe KE, Leppla SH, Moayeri M. 2008. Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome. Cell. Microbiol. 10: 332-43
273. Wigelsworth DJ, Krantz BA, Christensen KA, Lacy DB, Juris SJ, CollierRJ. 2004. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J. Biol. Chem. 279: 23349-56
274. Wright GG, Mandell GL. 1986. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. 164: 1700-9
275. Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, et al. 2014. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. Vaccine 32: 1019-28
276. Xu L, Fang H, Frucht DM. 2008. Anthrax lethal toxin increases superoxide production in murine neutrophils via differential effects on MAPK signaling pathways. J. Immunol. 180: 4139-47
277. Yan M, Roehrl MH, Basar E, Wang JY. 2007. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine 26: 947-55
278. Yang J, Woo SS, Ryu YH, Yun CH, Cho MH, et al. 2009. Bacillus anthracis lethal toxin attenuates lipoteichoic acid-induced maturation and activation of dendritic cells through a unique mechanism. Mol. Immunol. 46: 3261-68
279. Yeager LA, Chopra AK, Peterson JW. 2009. Bacillus anthracis edema toxin suppresses human macrophage phagocytosis and cytoskeletal remodeling via the protein kinaseAand exchange protein activated by cyclic AMP pathways. Infect. Immun. 77: 2530-43